Brief: Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress
28/10/2025 12:50
Oct 28 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA PRESENTS LP-284 CLINICAL DATA AT 25TH LL&M CONGRESS, HIGHLIGHTING COMPLETE RESPONSE IN THERAPEUTICALLY EXHAUSTED DLBCL PATIENT & THERAPEUTIC POTENTIAL IN ADVANCED B-CELL CANCERS. Source text: ID:nBw8TG6w6a Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments